{"name":"Arcutis Biotherapeutics, Inc.","slug":"arcutis-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"Roflumilast Cream 0.15%","genericName":"Roflumilast Cream 0.15%","slug":"roflumilast-cream-0-15","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Roflumilast Foam 0.3%","genericName":"Roflumilast Foam 0.3%","slug":"roflumilast-foam-0-3","indication":"Atopic dermatitis (topical foam formulation)","status":"phase_3"},{"name":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","genericName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","slug":"arq-151-cream-0-15-or-arq-151-cream-0-05","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-151 cream 0.15%","genericName":"ARQ-151 cream 0.15%","slug":"arq-151-cream-0-15","indication":"Plaque psoriasis","status":"phase_1"},{"name":"ARQ-151 cream 0.3%","genericName":"ARQ-151 cream 0.3%","slug":"arq-151-cream-0-3","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-151 vehicle cream","genericName":"ARQ-151 vehicle cream","slug":"arq-151-vehicle-cream","indication":"Atopic dermatitis","status":"phase_3"},{"name":"ARQ-154","genericName":"ARQ-154","slug":"arq-154","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"Roflumilast Cream 0.05%","genericName":"Roflumilast Cream 0.05%","slug":"roflumilast-cream-0-05","indication":"Atopic dermatitis (topical)","status":"phase_3"},{"name":"Roflumilast Foam","genericName":"Roflumilast Foam","slug":"roflumilast-foam","indication":"Atopic dermatitis (topical foam formulation)","status":"phase_3"},{"name":"Topical roflumilast","genericName":"Topical roflumilast","slug":"topical-roflumilast","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ARQ-234","genericName":"ARQ-234","slug":"arq-234","indication":"Other","status":"phase_1"},{"name":"ARQ-151 cream 0.5%","genericName":"ARQ-151 cream 0.5%","slug":"arq-151-cream-0-5","indication":"Other","status":"phase_1"},{"name":"ARQ-154 Foam 0.3%","genericName":"ARQ-154 Foam 0.3%","slug":"arq-154-foam-0-3","indication":"Other","status":"phase_1"},{"name":"ARQ-252 cream 0.1%","genericName":"ARQ-252 cream 0.1%","slug":"arq-252-cream-0-1","indication":"Other","status":"phase_1"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ARQ-151 cream 0.05%","genericName":"ARQ-151 cream 0.05%","slug":"arq-151-cream-0-05","indication":"Atopic dermatitis","status":"phase_2"}]}],"pipeline":[{"name":"ARQ-234","genericName":"ARQ-234","slug":"arq-234","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Roflumilast Cream 0.15%","genericName":"Roflumilast Cream 0.15%","slug":"roflumilast-cream-0-15","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation by blocking the action of phosphodiesterase 4.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"Roflumilast Foam 0.3%","genericName":"Roflumilast Foam 0.3%","slug":"roflumilast-foam-0-3","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","indications":["Atopic dermatitis (topical foam formulation)","Plaque psoriasis (topical foam formulation)"],"catalyst":""},{"name":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","genericName":"ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%","slug":"arq-151-cream-0-15-or-arq-151-cream-0-05","phase":"phase_3","mechanism":"ARQ-151 is a selective aryl hydrocarbon receptor (AhR) agonist that modulates immune responses in the skin to reduce inflammation.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.05%","genericName":"ARQ-151 cream 0.05%","slug":"arq-151-cream-0-05","phase":"phase_2","mechanism":"ARQ-151 is a selective Janus kinase 1 (JAK1) inhibitor that modulates cytokine signaling involved in inflammatory responses.","indications":["Atopic dermatitis"],"catalyst":""},{"name":"ARQ-151 cream 0.15%","genericName":"ARQ-151 cream 0.15%","slug":"arq-151-cream-0-15","phase":"phase_1","mechanism":"ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.3%","genericName":"ARQ-151 cream 0.3%","slug":"arq-151-cream-0-3","phase":"phase_3","mechanism":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-151 cream 0.5%","genericName":"ARQ-151 cream 0.5%","slug":"arq-151-cream-0-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARQ-151 vehicle cream","genericName":"ARQ-151 vehicle cream","slug":"arq-151-vehicle-cream","phase":"phase_3","mechanism":"ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.","indications":["Atopic dermatitis","Plaque psoriasis"],"catalyst":""},{"name":"ARQ-154","genericName":"ARQ-154","slug":"arq-154","phase":"phase_2","mechanism":"ARQ-154 is a topical Janus kinase (JAK) inhibitor.","indications":["Moderate to severe atopic dermatitis","Moderate to severe psoriasis"],"catalyst":""},{"name":"ARQ-154 Foam 0.3%","genericName":"ARQ-154 Foam 0.3%","slug":"arq-154-foam-0-3","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARQ-252 cream 0.1%","genericName":"ARQ-252 cream 0.1%","slug":"arq-252-cream-0-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Roflumilast Cream 0.05%","genericName":"Roflumilast Cream 0.05%","slug":"roflumilast-cream-0-05","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","indications":["Atopic dermatitis (topical)","Plaque psoriasis (topical)"],"catalyst":""},{"name":"Roflumilast Foam","genericName":"Roflumilast Foam","slug":"roflumilast-foam","phase":"phase_3","mechanism":"Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and inflammatory cells.","indications":["Atopic dermatitis (topical foam formulation)","Plaque psoriasis (topical foam formulation)"],"catalyst":""},{"name":"Topical roflumilast","genericName":"Topical roflumilast","slug":"topical-roflumilast","phase":"phase_3","mechanism":"Topical roflumilast is a phosphodiesterase 4 inhibitor that reduces inflammation in the skin.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNcTJnVHl4bUFFbF93Y2V4RlpsZDB1ektuNTI4VzB5aXlfUjU4NnF2Z3QwY3VISmw3dkhLT1dfTU5FdlkyWVc1bEU5UW80MzY4R1VtSTRKZXc4RnVrRUJqdHFma0EyTkpLbkRqY1ZiTDlFUHN6QmxDaXV5OG5mTGdhMmgwNTVEOVBQS0dDQ3NMbExHQmhvNWZlcGhadHBnUjAyR3pTS1VnbUIwbUhjYnRrRG5qMmtVMUFCRkJOZExzUW03VjNzRlY2NHhXa1R3dF9mVjJsdkg1REpCLVZVaTEwNlgzdTJRWkJyVzBjMGFkVVJwdE9ka1QtdllYNmFhT1dZc2Y3ckFXb3pHLUFtV1NZNFJiTExkVHBaMjQ3SUdNQ0pHelVleTN5NTMwQjRLU1UzX0ZRdGhqSjY5VEx0d1dncXJZYUdfQm5BbzdhZ1hyQQ?oc=5","date":"2026-03-23","type":"regulatory","source":"Barchart.com","summary":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - ","headline":"Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUM3SDdEZHdFcHV1Y0pVckI2Y0RrVERCYVhEUS1lWUhNdUVObDY0VTFZbjEwM2R4dkt1a3hsTG50ck9ObnlMQXB5M2lkMm1yQ0pTSS12cnVWeG51V0tKU1JLbko2aXZ3M25UOFJGTkxUUWZ0RG0zb19hYmM1NHFucUZueE1POXJtb3QxSlczZmZzWC1LdDcyUHU2S3IyU29VSnJDWW9OZjJPdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Medscape","summary":"Tachyphylaxis in Psoriasis: What’s Really Happening? - Medscape","headline":"Tachyphylaxis in Psoriasis: What’s Really Happening?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxORFROenR3UHdaMmJSMndiWWJUVGZtWkZXb0dMY1NMdXk1OW8xSm5UUUxWWEFVTFpIOTJzUm8tN3hsc1I5WWhMaVBGbmF1ZER3Mnk1ckdMeXlGejMxRnAyS1BkSGpiUDJQR1NaYUlPbE5hOEJnaHVDalo4TnRiV011d0lPYmZxcWhp?oc=5","date":"2026-03-02","type":"pipeline","source":"BioWorld News","summary":"Adquey finds hatchway, still more in PDE4 - BioWorld News","headline":"Adquey finds hatchway, still more in PDE4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNRHJDUWJSQVlZeTFnNkZ2VzNONFBwMjdNbkxRUnc4UXNVbWZsRGdiUk9iRDg2OEVMYnIzbWhoYVNpb0xwZ1FKTGt0UnVucWtzU1gwT1FIckJzLXYtZWZId2d6clhmY2hSbmtmQlFTUFVuV21xMmtvX251N3FFWkpWQUZORGtyT3NHVnJWZFlNZFB3M0R5MFIyUExXa1JJeHhqLXFF?oc=5","date":"2026-01-27","type":"pipeline","source":"Yahoo Finance","summary":"Arcutis Biotherapeutics announces termination of promotion agreement with Kowa - Yahoo Finance","headline":"Arcutis Biotherapeutics announces termination of promotion agreement with Kowa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPaFY0akl4bkdJZ1VVWFp1RVVlVmtDdTVwOTFhaGFzZF9zSkJnQlR1eDB1ZnpQZFlsTnRJeVA0azBaZ2RwV1JXdkIyTk5YUHFXbXlyek0wWDNCWXVId0ZEQ1hxamxqcWJiakRsWE16bktHSVdiYlRLN3JHcDhtd2laa2pBZjEyUVQ3NzBQZ19oYVlzQkt3MVZYYW4xVm5EczNhcFBXSHpmQ1RPSF9wd3RwUHV3cEp3MjBjNUE?oc=5","date":"2026-01-26","type":"deal","source":"Fierce Pharma","summary":"Arcutis, Kowa part ways on US marketing partnership for Zoryve - Fierce Pharma","headline":"Arcutis, Kowa part ways on US marketing partnership for Zoryve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNNTRLTnhFQ3gxWWU3cTFSU3E5WG5wTURQYUJXd3Ztbi1nWnU2VTNTMzNhU0VwZVNyb0NXTVdIRjl1eFNnREgwOHpPUnVoMV9uVmRmZmVUNnFrcUZMQTRLVzFiUEFuWXFHdHFHaFRCVlQtM1BqRGt6WlRKaGNZd2tVdXgyT0hpN203eHQzamZMRWdwVGxybDAzUUsybDhoZGJRbFNRY0RqY2hXZU9kXzJfX0Z6MHYzRGM?oc=5","date":"2026-01-26","type":"pipeline","source":"Investing.com","summary":"Arcutis terminates promotion agreement with Kowa for ZORYVE - Investing.com","headline":"Arcutis terminates promotion agreement with Kowa for ZORYVE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOSi1obGp1bjM1ZWtjT0stdW9vNXduTkM0LUdEMVhKUF9zdHp2S09mbzFfQVZmLUhSNXNDSWpWLVlxbXVHczBkOWQySjFSOUp2M2FKekNkYzIzWTU0TnliX05hd1VUZjc3WFlVakVWSi1kZjVxQ0Z0TXZlaG1uOFl0ZURVc0ROeW1FWjVwaGZSd1V1Mkl2ZklBcjloQXR0YU1tTDMxcDg2bVRVTUVjNlRuWkthenhzMzFt?oc=5","date":"2026-01-26","type":"pipeline","source":"Stock Titan","summary":"Arcutis to sell ZORYVE to primary care docs itself after Kowa exit - Stock Titan","headline":"Arcutis to sell ZORYVE to primary care docs itself after Kowa exit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5iMnB6d0RtaUtZcG5TTURBSFktUHN4X1Y5MFdZdG9jbHNNdGVoRW14Nzd6bHc4dzlTV2ZXa05YRm9wRjhLUGFvRmhRYXVIaVRQQzU3RC1iVEdPb1RGNEtTVDlYemFPUTJwYTQ0VTJ3dkhKR0ZQWmV6X2dn?oc=5","date":"2026-01-21","type":"pipeline","source":"BioCentury","summary":"Biotech’s year of the launch - BioCentury","headline":"Biotech’s year of the launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPZ2RnUVlUYlhVMHpscEo3TUFaQXBucFB1WXJWX3lDMXpWeXZEZlpUR0t0VndsUXVWQzRTUVd4emthRkY1TThuakVQMkFPSnBkbW85dzNvclkyRUwwVFB1a29qZ2xEclZ6VC1uSGx1Wi1Wa2pPSFRUNkZXTFFySVRWR3RXbEw2QmgxMEd1T1B6QnZrdDFNa3dGb29ncXBySlozNC1IQ0tlLVVsMC1mc0pJZmluQ1gtb19jYVJnOWFaREFXZXBzdkNCaTk0SmU?oc=5","date":"2025-12-17","type":"pipeline","source":"The Globe and Mail","summary":"5 Biotech Stocks to Watch for Potential Upside - The Globe and Mail","headline":"5 Biotech Stocks to Watch for Potential Upside","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOTEFlVTdVS3ZPQ3ZGbEwtS3loUVlzNVU2T0xOTlAzVWdCaUt2ZXlOSEV1d1VqSGxhc3g0c0g5dnJCRHpBSnU3M2N5cllqa2xyUXF3MTR2ajRGYXdaX3l6Wi1JdDQ0RWNTWWdsNVFTdjlWQTVkOXA3WlNYRVFSNXNyMXd4bTNGVUdoYVY3ZkhMWlVzUU05aEdSX25GWC1Yd0ZNYzdhU0JtS183MVAy?oc=5","date":"2025-11-04","type":"pipeline","source":"Fierce Pharma","summary":"Arcutis taps '90210' star power to spell out the needs of people with skin conditions - Fierce Pharma","headline":"Arcutis taps '90210' star power to spell out the needs of people with skin conditions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxORDU1STg1S1VuTWZtV0YxNDJlRklDcmxIMGRBRTNwcm9YMkZYQXVFRTdoY09EaTJoTVA4WHJnd1BBcmduR1VwWVJQLVBQcWF3UzFqQ0hEQnRVN29aZTVZQVpJQ3lhLWFmYWI3djVYLVh2TmhBbzhsZ3NwbzhSRWNpZlJCX2RrajJleFE?oc=5","date":"2025-09-13","type":"pipeline","source":"TIKR.com","summary":"9 of the Fastest-Growing Biotech Stocks Under $10 Billion - TIKR.com","headline":"9 of the Fastest-Growing Biotech Stocks Under $10 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQdGZvc3BHTmxjdkFEdWk4V2U1VXRiXzRUMEIyeXp5U181ZHVNTHpBWnNCaXNIbDl2cm9rY0JVVlo3N2liUlFTS2R4TTQ0OW02WW82S0FNQi11TVdRYVpXcUI4QkR4N1ViWmRrc2NkNjk3NzhpcUpzVTZZdERlT2tpNlVSQ1BQdUIxY0c5dXp3WE8?oc=5","date":"2025-04-11","type":"pipeline","source":"Contract Pharma","summary":"Arcutis Names New Chief Financial Officer - Contract Pharma","headline":"Arcutis Names New Chief Financial Officer","sentiment":"neutral"}],"patents":[],"drugCount":15,"phaseCounts":{"phase_1":5,"phase_3":8,"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}